• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer

    4/20/26 7:00:00 AM ET
    $LMRI
    Medical Specialities
    Health Care
    Get the next $LMRI alert in real time by email

    RALEIGH, N.C., April 20, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ:LMRI), one of the nation's largest providers of outpatient imaging services, today announced the appointment of Kyle Lynch as its new Chief Growth Officer (CGO). Lynch joins the executive leadership team to lead the company's enterprise growth strategy, with responsibility for expanding Lumexa Imaging's platform through joint ventures, acquisitions, and de novo development.

    In this role, Lynch will oversee the full growth lifecycle, including opportunity origination, transaction execution, and post-close value realization, with a focus on driving sustainable, profitable growth and maximizing return on invested capital. He will work closely with the CEO, CFO, Chief Strategy Officer, and operations leadership to ensure growth initiatives are tightly aligned with Lumexa Imaging's clinical excellence, operational performance, and long-term financial objectives.

    "Kyle brings a powerful combination of strategic insight, execution discipline, and commercial leadership," said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. "At a time when outpatient imaging is benefiting from strong secular tailwinds—including site-of-care migration, growing demand for advanced diagnostics, and a highly fragmented provider landscape, his track record of scaling growth platforms and delivering measurable results will be instrumental as we drive same-center performance and accelerate disciplined geographic expansion."

    Lynch will also lead Lumexa Imaging's Sales Center of Excellence, advancing a scalable, data-driven commercial model across the enterprise. His focus will include enhancing sales productivity, standardizing performance metrics, and driving consistent referral growth and same-center performance across Lumexa Imaging's national footprint.

    "Lumexa Imaging has built a differentiated platform grounded in clinical excellence, operational rigor, and a strong patient and provider experience," said Lynch. "I look forward to partnering with the leadership team to scale that platform, expand access to high-quality care, and deliver long-term value for patients, partners, and shareholders."

    Prior to joining Lumexa Imaging, Lynch served as SVP of Strategy and Development at SCA Health, where he led enterprise growth initiatives across a national healthcare services platform. He brings deep experience in building high-performing business development organizations, executing complex transactions, and driving growth strategies that translate into durable financial performance.

    About Lumexa Imaging

    Lumexa Imaging is a nationwide provider of outpatient medical imaging. With over 5,000 team members and more than 185 outpatient imaging centers across 13 states, our team conducted approximately 4 million outpatient procedures system-wide in 2025. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," or "will," or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our ability to drive future growth and execute on our goals, strategies and long-term objectives. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including but not limited to those risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of our Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (SEC). The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.

    Media Contact

    Melissa Weston

    [email protected]

    IR Contact

    Sue Dooley

    [email protected]



    Get the next $LMRI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LMRI

    DatePrice TargetRatingAnalyst
    2/9/2026$23.00Outperform → Strong Buy
    Raymond James
    1/5/2026$23.00Overweight
    Analyst
    1/5/2026$23.00Buy
    Jefferies
    1/5/2026$22.00Overweight
    Wells Fargo
    1/5/2026Outperform
    William Blair
    1/5/2026$23.00Outperform
    Raymond James
    1/5/2026$23.00Outperform
    Leerink Partners
    1/5/2026$22.00Buy
    Deutsche Bank
    More analyst ratings

    $LMRI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer

    RALEIGH, N.C., April 20, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ:LMRI), one of the nation's largest providers of outpatient imaging services, today announced the appointment of Kyle Lynch as its new Chief Growth Officer (CGO). Lynch joins the executive leadership team to lead the company's enterprise growth strategy, with responsibility for expanding Lumexa Imaging's platform through joint ventures, acquisitions, and de novo development. In this role, Lynch will oversee the full growth lifecycle, including opportunity origination, transaction execution, and post-close value realization, with a focus on driving sustainable, profitable growth and maximizing return on invested capita

    4/20/26 7:00:00 AM ET
    $LMRI
    Medical Specialities
    Health Care

    Lumexa Imaging Announces Fourth Quarter and Full Year 2025 Results, Reiterates Full Year 2026 Guidance

    RALEIGH, N.C., March 26, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ:LMRI), one of the nation's largest providers of outpatient imaging services, today announced certain financial results for the fourth quarter ended December 31, 2025, and reiterated full year 2026 guidance. The financial results included in this release pertaining to the fourth quarter and full year 2025 are preliminary, unaudited, and subject to final review and adjustment. "The fourth quarter of 2025 marked a strong close to an important year for Lumexa Imaging, with continued momentum across the business," said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. "Strong Adjusted EBITDA growth was driven by a

    3/26/26 6:00:00 AM ET
    $LMRI
    Medical Specialities
    Health Care

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    $LMRI
    SEC Filings

    View All

    Lumexa Imaging Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Lumexa Imaging Holdings, Inc. (0002071288) (Filer)

    4/9/26 5:11:27 PM ET
    $LMRI
    Medical Specialities
    Health Care

    SEC Form 10-K filed by Lumexa Imaging Holdings Inc.

    10-K - Lumexa Imaging Holdings, Inc. (0002071288) (Filer)

    3/30/26 5:32:34 PM ET
    $LMRI
    Medical Specialities
    Health Care

    Lumexa Imaging Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Lumexa Imaging Holdings, Inc. (0002071288) (Filer)

    3/26/26 6:09:21 AM ET
    $LMRI
    Medical Specialities
    Health Care

    $LMRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lumexa Imaging Holdings upgraded by Raymond James with a new price target

    Raymond James upgraded Lumexa Imaging Holdings from Outperform to Strong Buy and set a new price target of $23.00

    2/9/26 8:16:45 AM ET
    $LMRI
    Medical Specialities
    Health Care

    Analyst initiated coverage on Lumexa Imaging Holdings with a new price target

    Analyst initiated coverage of Lumexa Imaging Holdings with a rating of Overweight and set a new price target of $23.00

    1/5/26 9:16:52 AM ET
    $LMRI
    Medical Specialities
    Health Care

    Jefferies initiated coverage on Lumexa Imaging Holdings with a new price target

    Jefferies initiated coverage of Lumexa Imaging Holdings with a rating of Buy and set a new price target of $23.00

    1/5/26 8:58:21 AM ET
    $LMRI
    Medical Specialities
    Health Care

    $LMRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Walker James Edward Jr. was granted 12,414 shares, increasing direct ownership by 252% to 17,346 units (SEC Form 4)

    4 - Lumexa Imaging Holdings, Inc. (0002071288) (Issuer)

    2/27/26 5:40:01 PM ET
    $LMRI
    Medical Specialities
    Health Care

    Chief Financial Officer Martin James Anthony was granted 54,054 shares (SEC Form 4)

    4 - Lumexa Imaging Holdings, Inc. (0002071288) (Issuer)

    1/15/26 12:51:17 PM ET
    $LMRI
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Martin James Anthony

    3 - Lumexa Imaging Holdings, Inc. (0002071288) (Issuer)

    1/15/26 12:49:28 PM ET
    $LMRI
    Medical Specialities
    Health Care

    $LMRI
    Leadership Updates

    Live Leadership Updates

    View All

    Lumexa Imaging Appoints Kyle Lynch as Chief Growth Officer

    RALEIGH, N.C., April 20, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ:LMRI), one of the nation's largest providers of outpatient imaging services, today announced the appointment of Kyle Lynch as its new Chief Growth Officer (CGO). Lynch joins the executive leadership team to lead the company's enterprise growth strategy, with responsibility for expanding Lumexa Imaging's platform through joint ventures, acquisitions, and de novo development. In this role, Lynch will oversee the full growth lifecycle, including opportunity origination, transaction execution, and post-close value realization, with a focus on driving sustainable, profitable growth and maximizing return on invested capita

    4/20/26 7:00:00 AM ET
    $LMRI
    Medical Specialities
    Health Care

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials